51ÁÔÆæ

Susan Schniepp, 51ÁÔÆæ Inc., discusses digital twins and AI in pharma, focusing on data integrity, human-in-the-loop roles, and evolving machine learning risks in this publication from PharmTech. Link...

In this video article published by PharmTech, Susan Schniepp says poor quality in pharma manufacturing is costly but catching defects early can saves millions. Link to the Video and Article...

In this episode of Ask the Expert, published by PharmTech. Susan J. Schniepp and Siegfried Schmitt discuss how companies should approach preventing product recalls. Link to the Video and Article...

In this brief expert walkthrough, we review the FDA’s latest guidance on responding to Form 483 observations and highlight what has changed and what it means for your organization. An...

Why Cybersecurity Has Become a Regulatory Priority As combination products increasingly rely on software, connectivity, and digital interfaces, cybersecurity has moved from a secondary concern to a core regulatory expectation....

Why Design Controls Are the Biggest Leap for Drug Teams For pharmaceutical and biologic organizations entering the combination product space, few regulatory requirements cause as much friction as design controls...